ArticleHealthcare (Basel, Switzerland)2023
Healthcare Systems across Europe and the US: The Managed Entry Agreements Experience.
Article in Healthcare (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- eHealth literacy in emergency care: a scoping review.BMC health services research · 2026Article
- Article
- Invisible Pillars With Hidden Burdens: A Scoping Review on the Challenges of Informal Caregivers for Older Adults in Home-Based Palliative Care.Journal of palliative care · 2026Article
- Bench to bedside: Bridging the gap.Indian journal of ophthalmology · 2026Article
- Evaluating National Health Systems: The Case of the General Health System of Cyprus Through a Survey.Health science reports · 2026Article
- Article
- From tradition to innovation: a bibliometric analysis of the evolution of periodontal plastic surgery.Journal of periodontal & implant science · 2025Article
- Bridging Clinical Outcomes and Cost-Effectiveness: The Role of Real-World Data in Cystic Fibrosis Therapy.Pharmacology research & perspectives · 2025Article
- Assessing the General Health System of Cyprus: a questionnaire analysis based on public perception.Archives of public health = Archives belges de sante publique · 2025Article
- Utilization and access to metered-dose inhalers and sustainable alternatives among older adults in the United States: a population-based study.Lancet regional health. Americas · 2025Article
- A Methodological Proposal for Health Technology Assessments: A Case Study on Biosimilar Drugs.Journal of market access & health policy · 2025Article
- Variations in the Medical Device Authorization and Reimbursement Landscape: A Case Study of 2 Cardiovascular Devices Across 4 Countries.Circulation. Cardiovascular quality and outcomes · 2025Article
- New Drug Expenditure by Therapeutic Area in South Korea: International Comparison and Policy Implications.Healthcare (Basel, Switzerland) · 2025Article
- AI-Driven Analysis of Drug Marketing Efficiency: Unveiling FDA Approval to Market Release Dynamics.The AAPS journal · 2025Article
- Article
- Comparing Perspectives on Traditional and Complementary Medicine Use in Oncology: Insights from Healthcare Professionals and Oncology Patients in Western Mexico.Current oncology (Toronto, Ont.) · 2025Article
- Article
- Burnout among intensivists and critical care fellows in South Korea: Current status and associated factors.PloS one · 2025Article
- Toward value in healthcare: opportunities and challenges for implementing Value-Based Healthcare in North Macedonia.Frontiers in public health · 2025Review
- Trends in Triptan Usage in Korea: A Population-Based Cohort Study.Journal of Korean medical science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This systematic study aims at analyzing the differences between the approach of the European healthcare systems to the pharmaceutical market and the American one. This paper highlights the opportunities and the limitations given by the application of managed entry agreements (MEAs) in European countries as opposed to the American market, which does not regulate pharmaceutical prices. Data were collected from the Organisation for Economic Co-operation and Development (OECD), the European Medicines Agency, and the national healthcare agencies of US and European countries. A literature review was undertaken in PubMed, Scopus, MEDLINE, and Google for a period ten years (2010-2019). The period 2020-2021 was considered to compare health expenditure before and after the SARS-CoV-2 pandemic. Scarce information from national agencies has been given in terms of MEAs related to the COVID-19 pandemic. The comparison between the United States approach and the European one shows the importance of a market access regulation to reduce the cost of therapies, increasing the efficiency of national healthcare systems and the advantages in terms of quality and accessibility to the final users: patients. Nevertheless, it seems that the golden age of MEAs for Europe was during the examined period. Except for Italy, countries will move to other forms of reimbursements to obtain higher benefits, reducing the costs of an inefficient implementation and outcomes in the medium term.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.